---
title: 'Scientist II, Cellular Neuroscience and Translational Pharmacology at Lexeo Therapeutics'
canonical: 'https://feeny.ai/job/scientist-ii-cellular-neuroscience-and-translational-pharmacology-lexeo-b4597dp1w5gp'
type: 'job'
last_seen: '2026-10-19'
---

# Scientist II, Cellular Neuroscience and Translational Pharmacology at Lexeo Therapeutics

- **Company:** Lexeo Therapeutics
- **Location:** New York, NY
- **Compensation:** $127k–$150k
- **Employment:** full-time
- **Work type:** onsite
- **Posted:** 2026-10-13
- **Last confirmed live:** 2026-10-19
- **Apply:** https://jobs.lever.co/lexeotx/ae2635e3-be93-4a3b-942d-fc36418a175d

## Job description

## Role Summary

We are seeking a highly collaborative, hands-on Scientist II to help establish a preclinical neuroscience laboratory supporting small-molecule and protein therapeutics. The immediate priorities are rapid cellular profiling and lead selection for an advanced small-molecule enzyme program, and leadership of cellular development for a transferrin-based protein replacement project. The role will also build fit-for-purpose human neuronal models, laboratory workflows, and external partnerships. Location We welcome applications from candidates located across the Northeast and Mid-Atlantic.

Primary Responsibilities

- Lead a rapid, tiered cellular assay strategy for small-molecule lead optimization, including target engagement, pharmacodynamics, concentration-response, duration, selectivity, neuronal phenotype, stress, and tolerability
- Lead cellular development of a transferrin-based protein replacement project by establishing quantitative assays for construct uptake, internalization, intracellular trafficking, protein abundance and integrity, mitochondrial response, and disease-relevant phenotypic rescue
- Use orthogonal methods to distinguish surface-bound, internalized, degraded, and functionally delivered protein; compare constructs and define advancement criteria
- Establish fit-for-purpose neuronal culture models, including iPSC-derived neurons or glia where they add decision value, with appropriate banking and quality control
- Define assay controls, acceptance criteria, reproducibility standards, analysis plans, SOPs, sample tracking, and electronic documentation
- Translate data into concise recommendations to advance, modify, or discontinue assets
- Partner across protein engineering, chemistry, bioanalysis, DMPK, pathology, computational biology, and in vivo pharmacology; scientifically manage CROs and assay transfers
- Mentor junior scientists and build workflows that are reproducible across operators. Future scope may include ASO screening in partnership with external experts

Required Skills and Qualifications

- PhD in pharmacology, neuroscience, molecular biology, chemical biology, cell biology, or a related discipline, plus 1 to 3 years of biotechnology or pharmaceutical industry experience
- Demonstrated experience in cellular pharmacology, assay development, and iterative drug discovery or lead optimization
- Hands-on experience with neuronal cell culture models, preferably human iPSC-derived neurons or glia
- Expertise in concentration-response, time-course, target-engagement, pharmacodynamic, quantitative data-analysis, and troubleshooting studies
- Concrete examples of scientific ownership in which an assay, platform, or data package influenced a program decision
- Excellent communication skills and willingness to maintain a substantial hands-on laboratory presence

## Preferred Skills and Qualifications

- Enzyme biology, epigenetics, or transcriptional pharmacology; therapeutic proteins or targeted-delivery constructs; cellular uptake, trafficking, or protein quantification; mitochondrial functional assays; high-content imaging or neuronal functional assays; transferrin receptor biology, BBB transport, or biodistribution; laboratory start-up, assay transfer, or CRO management
- Exposure to ASO screening or RNA pharmacology is beneficial

## About LEXEO

Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need. LEXEO Therapeutics is an EEO employer committed to an exciting, diverse, and enriching work environment.

## About Lexeo Therapeutics

## Company Overview
- **One-liner**: Lexeo Therapeutics is a clinical-stage genetic medicine company pioneering gene therapies to treat the root causes of inherited cardiovascular diseases and APOE4-associated Alzheimer’s disease.
- **Entity Type**: Public (NYSE: LXEO) – IPO in 2023
- **Headquarters**: New York, New York, United States (345 Park Avenue South, Floor 6)
- **Founded**: 2018
- **Founders**: Ronald Crystal, MD (Founder & Chief Scientific Adviser)

## Core Business
- **Primary industry/industries**: Biotechnology / Genetic Medicine / Gene Therapy
- **Target customers**: B2B (healthcare providers, clinical research institutions, patients via healthcare systems) – focus on larger-rare and prevalent cardiovascular indications with high unmet need.
- **Mission or purpose statement**: “Reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated” (from 10-K) – also “going beyond treating the symptoms of genetic disease by trying to stop its progress at its underlying cause” (from careers page).

## Products & Services
- **LX2006**: Gene therapy candidate for cardiomyopathy associated with Friedreich’s Ataxia (FA). Currently in Phase 1/2 SUNRISE-FA trial; positive interim data reported in 2025/2026. Plans to initiate a registrational study (SUNRISE-FA 2) in H1 2026.
- **LX2020**: Gene therapy candidate for arrhythmogenic cardiomyopathy (ACM) caused by PKP2 mutations. In Phase 1/2 HEROIC-PKP2 trial; positive interim data announced January 2026.
- **Preclinical pipeline**: Additional programs targeting hypertrophic cardiomyopathy, APOE4-associated Alzheimer’s disease, and other genetically defined conditions.

## Market Standing
- **Valuation/Market Cap**: $329.6 million (as of recent data from LinkedIn, 2026)
- **Key Metric**: Annual revenue of $654K (pre-commercial, clinical-stage); total funding not directly disclosed but backed by IPO and institutional investors.
- **Notable Investors/Partners**: Partnerships with Weill Cornell Medicine and University of California San Diego; institutional investors include those common in biotech IPOs (specific names not listed in provided sources).
- **Growth Signals**: 
  - Headcount grew 18.5% YoY to 81 employees (LinkedIn).
  - Positive interim clinical data for both lead programs.
  - FDA feedback expected Q2 2026 for registrational trial design.
  - Expanded pipeline into AI/Data Science for drug discovery (new Sr. Director role posted).

## Competitive Advantages
- **AAVrh10 vector technology**: High transduction efficiency in myocardial cells, lower toxicity potential, and low pre-existing immunity compared to other AAV serotypes.
- **Focus on larger-rare cardiovascular diseases**: Targeting conditions with high unmet need and no approved treatments, enabling a stepwise, capital-efficient development approach.
- **Strong academic partnerships**: Groundbreaking research from Weill Cornell and UCSD provides foundational science and credibility.
- **Full ownership**: Retains exclusive worldwide development and commercialization rights to all product candidates.

## Strategic Focus
- **Late-stage clinical advancement**: Pushing LX2006 and LX2020 toward registrational trials and potential BLA submission.
- **AI and data science integration**: Hiring a Senior Director of AI and Data Science to accelerate decision-making across discovery, development, and operations.
- **Expanding pipeline**: Leveraging early proof-of-concept data to address larger-rare and prevalent indications beyond current lead programs.
- **Manufacturing and CMC**: Scaling up AAV manufacturing processes using Sf9/baculovirus and HEK-based systems.

## Why Work Here
- **Culture**: “Passion to change the arc of medicine” – a mission-driven environment focused on transformative gene therapies.
- **Work model**: Hybrid – 2 days/week in the New York City office, 3 days remote (from careers page).
- **Compensation & benefits**:
  - Competitive salaries (e.g., Director/Sr. Director Clinical Development: $247,500 – $382,000/year)
  - Health, dental, vision, mental health benefits
  - 401(K) with company match, performance bonus, company equity
  - Unlimited PTO, paid holidays, paid parental leave
  - Commuter benefits, tech stipend, stocked kitchen, in-office lunch stipend
  - Life and disability insurance
- **Team**: Led by pioneers in gene therapy and rare disease drug development; small but growing company (81 employees) offering high impact and cross-functional ownership.
- **EEO**: Committed to an exciting, diverse, and enriching work environment.

## Sources
1. [sec.gov](https://www.sec.gov/Archives/edgar/data/1907108/000119312526193939/ars_10-k_2025.pdf) – Form 10-K for FY2025 (filed March 2026)
2. [linkedin.com](https://linkedin.com/company/lexeo-therapeutics) – LinkedIn company page (employees, revenue, market cap)
3. [lexeotx.com](https://www.lexeotx.com/careers/) – Careers page (benefits, culture, hybrid policy, job postings)
4. [jobs.lever.co](https://jobs.lever.co/lexeotx) – Lever job board (open positions)
5. [lexeotx.com](https://www.lexeotx.com/team/) – Leadership team page (founder, executives)

## Other roles at Lexeo Therapeutics

- [Research Associate I/II, Preclinical Research (Contract)](https://feeny.ai/job/research-associate-i-ii-preclinical-research-contract-lexeo-therapeutics-new-5cprbry5kqq2) — New York, NY
- [Manager/Senior Manager, CMC Quality Control](https://feeny.ai/job/manager-senior-manager-cmc-quality-control-lexeo-therapeutics-new-york-ak1xnmwz3p3y) — New York, NY
- [Director/Senior Director, Clinical Development](https://feeny.ai/job/director-senior-director-clinical-development-lexeo-therapeutics-new-york-vkywdkr3hqn8) — New York, NY